NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Philippe E. Spiess, MD, MS, Panel Vice Chair
Subodh M. Lele, MD, Panel Member
Carly J. Cassara, MS, Guidelines Layout Specialist, NCCN
Lisa A. Gurski, PhD, Manager, Licensed Clinical Content, NCCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Thomas W. Flaig, MD, Panel Chair, has disclosed receiving grant/research support from Agensys, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., sanofi-aventis US, and SeaGen; serving as a scientific advisor for Janssen Pharmaceutica Products, LP, and Criterium Inc.; equity interest/stock options, intellectual property rights from Aurora Oncology; and serving as a consultant for Criterium Inc.
Rick Bangs, MBA, Panel Member, has disclosed serving as a scientific advisor for Nonagen Biosciences.
Sam S. Chang, MD, MBA, Panel Member, has disclosed serving as a scientific advisor for Genentech, Inc., Merck & Co., Inc., CG Oncology Inc., ImmunityBio, Nonagen Biosciences, Pacific Edge, Prokarium, TU Therapeutics Inc., and UroGen Pharma; serving as a consultant for Astellas Pharma US, Inc., CG Oncology Inc., and UroGen Pharma; owning equity interest/stock options for FOLDE, TU Therapeutics Inc., and Vesica Health; and receiving grant/research support from Janssen Pharmaceutica Products, LP, and ImmunityBio.
Terence Friedlander, MD, Panel Member, has disclosed serving as a consultant for AbbVie, Inc., Astellas Pharma US, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and SeaGen.
Mamta Parikh, MD, MS, Panel Member, has disclosed serving as a consultant for Bristol Myers Squibb, Exelixis Inc., Natera, and sanofi-aventis US; serving as a scientific advisor for Pfizer, Inc; and receiving grant/research support from Karyopharm Therapeutics.
Mark A. Preston, MD, MPH, Panel Member, has disclosed serving as a consultant for Bayer HealthCare, and Pfizer Inc.; and serving as a scientific advisor for Janssen Pharmaceutica Products, LP.
Arlene O. Siefker-Radtke, MD, Panel Member, has disclosed serving as a scientific advisor for AbbVie, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica, Bicycle Therapeutics, Bristol Myers Squibb, G1 Therapeutics, Genentech, Inc., Gilead Sciences, Inc., IDEAYA Biosciences, Immunomedics, Inc., Janssen Pharmaceutica Products, LP, Loxo Oncology, Inc., Merck & Co., Inc., Mirati Therapeutics, Inc., Nektar Therapeutics, SeaGen, and Taiho Pharmaceuticals, Co., Ltd.; and receiving grant/research support from Basilea Pharmaceutica, Bristol Myers Squibb, Janssen Pharmaceutica Products, LP, Loxo Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., and Nektar Therapeutics.
Tyler Stewart, MD, Panel Member, has disclosed serving as a scientific advisor to Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Pfizer Inc., and SeaGen; and receiving grant/research support from GRAIL.
Debasish Sundi, MD, Panel Member, has disclosed receiving grant/research support from Janssen Pharmaceutica Products, LP.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.